摘要
目的探讨解脲支原体gyrA和parC基因喹诺酮耐药决定区(QRDR)突变与喹诺酮类药物耐药的相关性。方法用支原体培养、鉴定和药敏一体化试剂盒分离获得42株解脲支原体并检测对3种喹诺酮类药物的耐药性,同时PCR法扩增临床分离株的gyrA和parC基因喹诺酮耐药决定区并进行测序分析。结果对3种喹诺酮均敏感1株,41株至少对1种药物呈现不同程度耐药。gyrA和parC基因喹诺酮耐药决定区测序发现上述敏感株和1株耐药株不发生突变,其余40株耐药株gyrA和parC基因发生D112E和(或)S83L突变。结论 3种喹诺酮类药物耐药均较严重,已不适合作为临床推荐用药,解脲支原体gyrA和parC基因喹诺酮耐药决定区突变与耐药密切相关。
Objective To analyze mutations in the quinolone -resistance -determining- region （QRDR） within genes of gyrA and parC patterns in gyrA and parC genes and quinolones resistance in ureaplasma urealyticum（Uu） isolates. Methods Mycoplasma detec- tion kits were used to culture and identificate mycoplasma as well as drug sensitivity. PCR and DNA sequencing were conducted to analyze QRDR associated genes of gyrA and parC in 42 isolates. Results Only 1 isolate susceptible to all quinolones. Fourty - one isolates showed varying degree resistance to at least one kind of quinolones. Sequencing analysis of gyrA and parC revealed that the susceptible i- solate and 1 resistance isolate had no mutation, Fourty resistance isolates had mutation of Dll2E and/or $83L in GyrA and ParC. Con- clusion Three quinolones should not be routine therapy for ureaplasma urealyticum infections. Mutations in gyrA and parC genes play an important role in the development of quinolones resistance in ureaplasma urealyticum.
出处
《医学研究杂志》
2012年第10期63-66,共4页
Journal of Medical Research
基金
浙江省医药卫生科学研究基金资助项目(2004A018)
